期刊
BLOOD
卷 117, 期 24, 页码 6638-6649出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2010-12-327346
关键词
-
类别
资金
- Aarhus University
- Karen Elise Jensen Foundation
- Max and Inger Worzner Foundation
- Foundation in Commemoration of Eva and Henry Fraenkel
- Aase and Ejner Danielsen Foundation
- Poul and Ellen Hertz Foundation
- Else and Mogens Wedell-Wedellsborg Foundation
- A. P. Moller and Chastine Mc-Kinney Moller Foundation for General Purposes
- Danish Cancer Research Foundation
- Gangsted Foundation
- John & Birthe Meyer Foundation
- Aarhus University Research Foundation
- Medical Research Council
- Villum Foundation
- Villum Fonden [00008721] Funding Source: researchfish
Considerable effort has been spent identifying prognostic biomarkers in classic Hodgkin lymphoma (cHL). The aim of our study was to search for possible prognostic parameters in advanced-stage cHL using a proteomics-based strategy. A total of 14 cHL pretreatment tissue samples from younger, advanced-stage patients were included. Patients were grouped according to treatment response. Proteins that were differentially expressed between the groups were analyzed using 2D-PAGE and identified by liquid chromatography mass spectrometry. Selected proteins were validated using Western blot analysis. One of the differentially expressed proteins, the carbohydrate-binding protein galectin-1 (Gal-1), was further analyzed using immunohistochemistry HC and its expression was correlated with clinicopathologic and outcome parameters in 143 advanced-stage cHLcases. At the univariate level, high Gal-1 expression in the tumor microenvironment was correlated with poor event-free survival (P = .02). Among younger (<= 61 years) patients, high Gal-1 was correlated with poorer overall and event-free survival (both P = .007). In this patient group and at the multivariate level, high Gal-1 expression retained a significant predictive impact on event-free survival. Therefore, in addition to its functional role in cHL-induced immunosuppression, Gal-1 is also associated with an adverse clinical outcome in this disease. (Blood. 2011;117(24):6638-6649)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据